Thymosin beta-4 and TB‑500: actin binding and repair research

Thymosin β4 was first studied as a possible hormone of the thymus gland. It turned out to be something more fundamental: one of the main proteins cells use to manage their supply of actin, the building block of the internal skeleton that lets them change shape and move. That role in cell movement led to decades of research into wound healing, cardiac repair and eye disease. TB-500, a short synthetic fragment of thymosin β4, has since become widely discussed in its own right. This article reviews both, and explains why findings for one cannot simply be transferred to the other.

From thymic hormone to actin buffer

The β-thymosins are a family of small, highly conserved, acidic peptides of about 5 kDa. They were originally thought to be thymic hormones. Around 1990 they were identified instead as the main molecules inside cells that bind monomeric actin (G-actin)^[1]. A 1991 study showed that thymosin β4 was identical to a previously described actin-sequestering peptide called Fx^[2].

Thymosin β4 binds actin monomers in a one-to-one complex. It prevents them from assembling into filaments, while keeping a reserve that the cell can draw on quickly when it needs to build new filaments^[1]. This buffering role is central to cell migration, which depends on rapid, local assembly and disassembly of actin.

Thymosin β4 is also found outside cells, in blood plasma and wound fluid. Several extracellular effects have been attributed to it, including stimulation of matrix-degrading enzymes, attraction of cells, formation of new blood vessels and reduced inflammation. As one review noted, however, the molecular mechanisms behind these extracellular effects were not understood^[1].

Cell migration and wound repair

Early work established thymosin β4 as a potent stimulator of cell movement. In endothelial cells, the cells lining blood vessels, it acted as a chemoattractant, increasing migration four- to six-fold in chamber assays. It also accelerated closure of scratch wounds in cell layers and increased production of matrix metalloproteinases^[3].

These findings were extended to whole animals. In a rat full-thickness skin wound model, thymosin β4 applied topically or by injection increased re-epithelialisation by 42% at day 4 and by up to 61% at day 7 compared with saline. Treated wounds contracted more and showed greater collagen deposition and angiogenesis. The peptide also stimulated keratinocyte migration two- to three-fold at very low concentrations^[4]. A later review brought together animal studies of thymosin β4 across multiple tissues^[5].

The heart and blood vessels

Some of the most widely cited thymosin β4 research concerns the heart. In a 2004 study, it promoted migration of heart muscle and endothelial cells in the embryonic heart, and survival of cardiomyocytes in culture. It formed a complex with two proteins, PINCH and integrin-linked kinase, which activated the survival kinase Akt. After coronary artery ligation in mice, thymosin β4 treatment increased this signalling, improved early survival of heart muscle cells and improved cardiac function^[6].

A 2007 study found that thymosin β4 is essential for coronary vessel development in mice. It also stimulated cells from the outer layer of the adult heart, the epicardium, to regain the capacity to form new vascular cells^[7].

Other groups have described signalling pathways linking thymosin β4 to blood vessel formation. It stimulated migration of endothelial progenitor cells through the PI3K–Akt–eNOS pathway^[8], and it promoted angiogenic behaviour of endothelial cells through Notch signalling^[9].

Reviews by researchers who have worked on thymosin β4 for many years bring these strands together. They describe roles in reducing cell death and inflammation, and in reducing myofibroblast numbers and scarring^[10].

TB-500 is not thymosin β4

TB-500 is a synthetic peptide of seven amino acids, acetylated at one end: Ac-LKKTETQ. It corresponds to the part of thymosin β4 associated with actin binding^[11]. The unacetylated sequence has been linked to actin binding, wound healing and angiogenesis. A 2024 analytical study pointed out, however, that the biological effects of TB-500 itself had not been documented^[11].

That study also examined how TB-500 is broken down. In human serum, enzyme systems and rats, the main metabolite was the dipeptide Ac-LK, while Ac-LKK was detectable in rat urine for up to 72 hours^[11]. Work of this kind matters in anti-doping analysis, and it highlights a basic point: a seven-residue fragment has a different structure, stability and fate in the body from the 43-residue parent protein.

Human studies

Human research has used full-length thymosin β4 in pharmaceutical formulations, not TB-500.

• Safety in healthy volunteers. A randomised, placebo-controlled phase 1 study gave intravenous thymosin β4 to four cohorts of ten healthy volunteers, as single doses and then daily for 14 days. Adverse events were infrequent and mild or moderate, with no dose-limiting toxicity or serious adverse events^[12].
• Severe dry eye. A small, randomised, double-masked phase 2 trial treated nine patients with thymosin β4 eye drops or a vehicle for 28 days. At day 56, the treated eyes showed a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal staining compared with vehicle, along with better tear measures^[13].
• Venous leg ulcers. A European randomised, placebo-controlled trial of topical thymosin β4 was designed to enrol 72 patients across Italy and Poland. The available publication describes its design and early enrolment rather than final efficacy results^[14].

A 2015 review described trials under way or planned in eye injuries, skin wounds, heart repair after myocardial infarction and brain injury^[15]. Taken together, the human evidence is promising in the eye but limited in size, and it is absent for TB-500.

Open questions

• Fragment activity. Does TB-500 reproduce the repair effects of the full protein in controlled studies, and at what exposure?
• Extracellular mechanism. How does extracellular thymosin β4 signal to cells? The receptor-level mechanism remains unclear^[1].
• Cell movement and cancer. Because β-thymosins increase cell mobility, higher expression has been proposed as a possible contributor to metastasis^[1]. Long-term safety needs careful study.
• Clinical translation. Larger, independent trials are needed beyond the small dry-eye study.

Summary

Thymosin β4 is a well-characterised actin-buffering protein with a substantial body of animal research on skin and cardiac repair, several independently described signalling pathways, and early human trials, the most encouraging in dry eye. TB-500 is a short synthetic fragment whose own biology has barely been studied. Treating evidence for the parent protein as evidence for the fragment is the most common error in discussions of this peptide, and one that careful readers should avoid.